Prima Retinal Implant System: Restoring Sight for Macular Degeneration Patients

Age-related macular degeneration (AMD) is a vision threat affecting over 5 million people worldwide. This disease erodes the central region of the retina, gradually robbing patients of their ability to read, recognize faces, and live independently. For a long time, the medical community had no way to address vision loss caused by AMD—until the Prima system came along.

According to RSS sources, this innovative solution—comprising a retinal implant and camera-equipped glasses—received European approval in July and is currently awaiting FDA marketing clearance in the United States. It offers AMD patients an entirely new pathway to restore vision through technological means.

AMD: An Overlooked Vision Killer

Macular degeneration affects the central macula region of the retina, which is responsible for the finest central vision. Patients find that the center of their visual field becomes blurry or develops a black spot, while peripheral vision remains intact. This "tunnel vision" makes reading, driving, and recognizing people extraordinarily difficult.

Of the over 5 million AMD patients worldwide, the vast majority have the dry form, with a minority having wet AMD. Existing treatments focus primarily on slowing disease progression—for example, anti-VEGF injections for wet AMD—but no method can reverse central vision that has already been lost. This is precisely where the Prima system's significance lies: it attempts to fill the gap between "treatment" and "rehabilitation."

The difference between dry and wet AMD: Dry AMD accounts for approximately 85%-90% of all cases, characterized pathologically by the appearance of drusen in the macular region—yellow lipid deposits that accumulate beneath the retinal pigment epithelium layer, causing gradual degeneration of photoreceptor cells. This process progresses slowly, typically over years or even decades. Although wet AMD accounts for only 10%-15% of cases, it is the primary cause of severe vision loss. Its core mechanism involves abnormal proliferation of choroidal neovascularization (CNV)—fragile new blood vessels that tend to leak and bleed, capable of rapidly destroying macular structure within weeks to months. Anti-VEGF drugs (such as ranibizumab and aflibercept) reduce leakage by inhibiting vascular endothelial growth factor, but require regular intraocular injections and are ineffective against dry AMD. Precisely because dry AMD has such a massive patient population and lacks effective therapies, the Prima system's choice to target central vision restoration carries significant clinical importance.

How the Prima System Works

The core concept behind Prima is to replace damaged photoreceptor cells with external devices. Patients wear a pair of glasses with a built-in camera; the camera captures external images and transmits them wirelessly to a microchip implanted beneath the retina. The chip converts light signals into electrical pulses, stimulating the remaining retinal neurons to produce visual perception in the brain.

This system bypasses the damaged photoreceptor cells in the macular region and directly activates downstream neural pathways. Patients require some training to adapt to this "artificial vision," but clinical trials show that some patients are able to regain a degree of reading ability. According to source descriptions, Prima "improved patients' vision" rather than merely halting deterioration.

The relationship between retinal pigment epithelium and photoreceptor cells: To understand how Prima works, one must first understand the layered structure of the retina. The deepest layer of the retina is the pigment epithelium layer (RPE), which provides nutrition to photoreceptor cells and clears metabolic waste; photoreceptor cells (rods and cones) sit above the RPE and are responsible for converting light signals into electrical signals; above them are bipolar cells and ganglion cells, which perform initial signal processing before transmitting signals through the optic nerve to the brain. AMD first damages the RPE and photoreceptor cells, but the downstream bipolar cells and ganglion cells often survive for extended periods. The Prima chip is implanted beneath the retina (i.e., between the choroid and the retina), bypassing the degenerated photoreceptor cells and directly stimulating still-viable retinal neurons with electrical pulses. This "bypass" strategy is a classic approach in the field of neuroprosthetics, previously successfully applied in cochlear implants and the Argus II system for certain patients with retinitis pigmentosa.

Regulatory Progress and Market Prospects

The Prima system received European CE certification in July, meaning it can be marketed and sold within the EU. Meanwhile, the developing company is submitting applications to the U.S. FDA, awaiting clearance. European approval provides a reference point for regulatory review in other global markets.

You may not have noticed, but neuro-implant devices of this kind typically require rigorous long-term safety and efficacy data. Prima's approval indicates that existing clinical evidence has met the requirements of European regulators. Opening the U.S. market will further expand its accessibility, but a specific timeline has not yet been clarified.

Regulatory differences between CE certification and FDA clearance: CE certification is the EU's mark indicating that a product meets health, safety, and environmental requirements; obtaining CE certification means a product can circulate freely within the European Economic Area. Unlike the FDA's premarket approval (PMA), CE certification in certain medical device categories uses a "notified body" review model, which may have relatively more flexible requirements for clinical evidence. For high-risk implantable devices, the EU has tightened regulation in recent years (MDR regulations), but Prima's ability to obtain CE certification indicates that its clinical data has met European standards. FDA clearance typically refers to the 510(k) pathway, applicable to low-to-moderate risk products that are substantially equivalent to already-marketed devices; however, as a novel implantable neuroprosthetic, Prima is more likely to follow the PMA pathway, requiring more rigorous randomized controlled trial data. Therefore, the U.S. approval timeline may be longer than Europe's, which is one reason the article mentions that "a specific timeline has not yet been clarified."

Technical Challenges and Future Directions

Retinal implants are not a new concept, but restoring central vision for AMD has always been a difficult problem. Prima's innovation lies in integrating the camera, processing unit, and implant into a wearable system, rather than relying on intraocular optical components.

Challenges remain: image resolution is limited, patients need to learn to interpret visual signals generated by electrical stimulation, and the biocompatibility of long-term implantation requires continuous monitoring. However, with advances in microelectronics and neural interface technology, such systems are expected to become smaller, more precise, and easier to use. For AMD patients, Prima represents not just a product, but a paradigm shift from "untreatable" to "restorable."